NT5E gene and CD38 protein as potential prognostic biomarkers for childhood B-acute lymphoblastic leukemia
Authors:
- Vitória Brum da Silva NunesVNVitória Brum da Silva Nunes
- Camila Kehl DiasCamila Kehl Dias
- Marco Antônio De BastianiMBMarco Antônio De Bastiani
- Mariela Granero FariasMFMariela Granero Farias
- Fabiane SpagnolFSFabiane Spagnol
- Ana Paula AlegrettiAAAna Paula Alegretti
- Liane Esteves DaudtLDLiane Esteves Daudt
- Mariana Bohns MichalowskiMariana Bohns Michalowski
- Ana Maria Oliveira BattastiniABAna Maria Oliveira Battastini
- Alessandra Aparecida PazAPAlessandra Aparecida Paz
- Fabrício FigueiróFFFabrício Figueiró
Open Access
- 2 March 2022
- journal article
- research article
- Published by Springer Nature in Purinergic Signalling
- Vol. 18 (2) , 211-222
Abstract
The risk stratification of B-acute lymphoblastic leukemia (B-ALL) is based on clinical and biological factors. However, B-ALL has significant biological and clinical heterogeneity and 50% of B-ALL patients do not have defined prognostic markers. In this sense, the identification of new prognostic biomarkers is necessary. Considering different cohorts of childhood B-ALL patients, gene (DPP4/CD38/ENTPD1/NT5E) and protein (CD38/CD39/CD73) expressions of ectonucleotidases were analyzed in silico and ex vivo and the association with prognosis was established. In univariate analyses, expression of NT5E was significantly associated with worse progression-free survival (PFS) in bone marrow (BM) samples. In multivariate analyses, Kaplan–Meier analysis, and log-rank test, higher NT5E expression predicted unfavorable PFS in BM samples. Considering minimal residual disease (MRD), higher levels of cellularity were associated with the high NT5E expression at day 8 of induction therapy. In addition, we observed that white blood cells (WBC) of childhood B-ALL patients had more CD38 compared to the same cell population of healthy donors (HD). In fact, MRD > 0.1% patients had higher CD38 protein expression on WBC in comparison to HD. Noteworthy, we observed higher CD38 expression on WBC than blasts in MRD > 0.1% patients. We suggest that NT5E gene and CD38 protein expression, of the ectonucleotidases family, could provide interesting prognostic biomarkers for childhood B-ALL.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (302879/2017–0)
- Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (19/2551–0001783-9, 19/2551–0001269-1, 16–2551-0000467–6)
- Instituto Nacional de Ciência e Tecnologia para Excitotoxicidade e Neuroproteção (465671/2014–4)
- Hospital de Clínicas de Porto Alegre (2018–0401)
This publication has 46 references indexed in Scilit:
- EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocolsLeukemia, 2012
- Extracellular nucleotides as negative modulators of immunityCurrent Opinion in Pharmacology, 2009
- Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarksGenes, Chromosomes and Cancer, 2008
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and PathologyPhysiological Reviews, 2008
- Extracellular NAD+ metabolism modulates osteoclastogenesisBiochemical and Biophysical Research Communications, 2006
- Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)Blood, 2006
- Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2Blood, 2006
- Comparison of gene-expression profiles in parallel bone marrow and peripheral blood samples in acute myeloid leukaemia by real-time polymerase chain reactionJournal of Clinical Pathology, 2006
- Relative Importance of CD38 Expression Over Myeloid-associated Markers Expression in Predicting the Clinical Course of B-CLL PatientsLeukemia & Lymphoma, 2003
- Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trialsLeukemia, 2000